Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravisPhase 2 TRITON trial of Descartes-08 in ...
Fintel reports that on March 9, 2026, Cantor Fitzgerald upgraded their outlook for Cartesian Therapeutics (NasdaqGM:RNAC) from Neutral to Overweight. Analyst Price Forecast Suggests 303.82% Upside As ...
FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results